Wells Fargo & Company Denali Therapeutics Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding DNLI
# of Institutions
217Shares Held
115MCall Options Held
127KPut Options Held
38.3K-
Baillie Gifford & CO13.3MShares$363 Million0.3% of portfolio
-
Black Rock Inc. New York, NY13.2MShares$358 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.3MShares$308 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA9.82MShares$267 Million0.04% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.13MShares$194 Million0.04% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $3.65B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...